Product Background
Worldwide infectious diseases claim more than 17 million deaths every year, with the most frequent causes of death being sepsis/SIRS, tuberculosis and HIV. In the US alone more than 700.000 patients per year fall ill with sepsis/SIRS, about 200.000 of them die from the condition. Not to mention the death toll by those diseases in thedeveloping world.With development of thesuPARnostic® marker ViroGates has succeeded in taking an important step towards global health monitoring.
suPARnostic® is a prognostic tool which allows early detection of a critical disease state in the body - with such knowledge life-saving intervention could be initiated earlier and monitored for success.
ViroGates focus is to make the suPARnostic® parameter available in various test formats, suitable for the different areas of healthcare management.
suPARnostic® assays are applied for the quantitative and semi-quantitative determination of soluble urokinase Plasminogen Activator Receptor (suPAR) in human EDTA plasma and whole blood. suPARnostic® is the first method to assign a reproducible clinical value to the suPAR parameter.
The suPARnostic® ELISA kits are simplified double monoclonal antibody sandwich assays whereby samples and peroxidase-conjugated anti-suPAR are first mixed together and then incubated in anti suPAR pre-coated microwells. The recombinant suPAR standards in the kit are calibrated against healthy human blood donor samples. suPAR concentrations determined with the kits are given as ng/mL plasma.
